Long-term follow-up of people with epilepsy who received the Minder device
Follows adults with epilepsy who previously received the Minder implantable brain monitoring system.
Plain-language title generated from the registry record
Registry title: Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
Key facts
- Where
- Ann Arbor, Billings, Birmingham, Boston, Charlotte, Cleveland, Durham, Indianapolis, Jacksonville, Miami, Minneapolis, New Haven, Palo Alto, Philadelphia, Phoenix, Rochester, San Diego, St Louis, and Tampa, United StatesSee the 20 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07110454, who can take part
Where in United States
- Michigan MedicineAnn Arbor, United StatesTaking people
- Billings ClinicBillings, United StatesTaking people
- UAB Epilepsy CenterBirmingham, United StatesTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- Atrium Health Neurosciences Institute ? CharlotteCharlotte, United StatesTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
- Duke UniversityDurham, United StatesTaking people
- IU Health Neuroscience CenterIndianapolis, United StatesEnrolling by invitation
- Mayo Clinic FloridaJacksonville, United StatesTaking people
- Nicklaus Children's HospitalMiami, United StatesTaking people
- University of MinnesotaMinneapolis, United StatesTaking people
- Yale School of MedicineNew Haven, United StatesTaking people
- StanfordPalo Alto, United StatesTaking people
- University of PennsylvaniaPhiladelphia, United StatesTaking people
- Mayo Clinic - ArizonaPhoenix, United StatesTaking people
- Mayo Clinic - RochesterRochester, United StatesTaking people
- UC San Diego HealthSan Diego, United StatesTaking people
- Washington UniversitySt Louis, United StatesTaking people
- USF HealthTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Epiminder America, Inc.
- Trial code
- NCT07110454
- Record updated
- 22 October 2026
- Original description
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational.Read full original descriptionShow less
A Prospective Long-Term Follow-Up Study to Evaluate the Use of the Minder Device to Aid in Treatment After Actionable Event Identification in Patients Diagnosed With Epilepsy.
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational.
Participants that have completed the DETECT study and received the Minder System previously will consent to join this long-term follow-up observational study. The study will collect information about general wellbeing, use of healthcare services, and experience using the Minder data over time to support long-term epilepsy care.
All participants will continue to be followed by their treating physician and undergo assessments and visits every six (6) months until two (2) years after receiving the Minder device.
Inclusion: Participant met all inclusion criteria, was enrolled in the DETECT study, and received the Minder device; Participant completed the DETECT study by receiving an actionable event or by completing the 6-month follow-up visit; Participant continues to have the Minder device implanted; Participant must continue to meet relevant DETECT study inclusion criteria.
Exclusion: Participant meets any relevant DETECT study exclusion criteria including needing treatments or assessments that are not indicated with the Minder System like Magnetic Resonance Imaging (MRI).